• HLS Therapeutics published its first-quarter fiscal 2026 MD&A, reporting revenue of USD 12.86 million versus USD 12.62 million a year earlier; adjusted EBITDA fell to USD 3.46 million from USD 3.82 million.
• Canadian product sales slipped 2% to CAD 13.67 million, reflecting an 11.5% drop in Clozaril sales to CAD 7.02 million; Vascepa sales rose 9.6% to CAD 6.55 million.
• Operating expenses excluding cost of product sales increased 5% year over year, driven by incremental spending ahead of NILEMDO launch; selling and marketing expense rose to USD 2.98 million from USD 2.83 million.
• Health Canada approval secured for NILEMDO; NEXLIZET received a Notice of Non-Compliance, with a response planned in second quarter fiscal 2026.
• Fiscal 2026 guidance maintained for revenue of USD 56-60 million, adjusted EBITDA of USD 18.5-21 million; cash totaled USD 12.33 million at quarter-end, with term facility principal outstanding of USD 44.2 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HLS Therapeutics Inc. published the original content used to generate this news brief on May 15, 2026, and is solely responsible for the information contained therein.